J Biol Chem, Vol. 274, Issue 43, 30864-30873, October 22, 1999
Differences in Signaling Properties of the Cytoplasmic
Domains of the Insulin Receptor and Insulin-like Growth Factor
Receptor in 3T3-L1 Adipocytes*
Birgitte
Ursø,
Diane L.
Cope,
Heidi E.
Kalloo-Hosein,
Amanda C.
Hayward,
Jon P.
Whitehead,
Stephen
O'Rahilly, and
Kenneth
Siddle
From the University of Cambridge, Department of Clinical
Biochemistry, Addenbrooke's Hospital,
Cambridge CB2 2QR, United Kingdom
 |
ABSTRACT |
Insulin and insulin-like growth factors (IGFs)
elicit distinct but overlapping biological effects in vivo.
To investigate whether differences in intrinsic signaling capacity of
receptors contribute to biological specificity, we constructed chimeric receptors containing the extracellular portion of the neurotrophin receptor TrkC fused to the intracellular portion of the insulin or
IGF-I receptors. Chimeras were stably expressed in 3T3-L1 adipocytes at
levels comparable to endogenous insulin receptors and were efficiently
activated by neurotrophin-3. The wild-type insulin receptor chimera
mediated approximately 2-fold greater phosphorylation of insulin
receptor substrate 1 (IRS-1), association of IRS-1 with
phosphoinositide 3-kinase, stimulation of glucose uptake, and GLUT4
translocation, compared with the IGF-I receptor chimera. In contrast,
the IGF-I receptor chimera mediated more effective Shc phosphorylation,
association of Shc with Grb2, and activation of mitogen-activated
protein kinase compared with the insulin receptor chimera. The two
receptors elicited similar activation of protein kinase B, p70S6
kinase, and glycogen synthesis. We conclude that the insulin receptor
mediates some aspects of metabolic signaling in adipocytes more
effectively than the IGF-I receptor, as a consequence of more efficient
phosphorylation of IRS-1 and greater recruitment/activation of
phosphoinositide 3-kinase.
 |
INTRODUCTION |
Insulin and insulin-like growth factors
(IGFs)1 are structurally
related polypeptides that exert diverse effects on mammalian tissues.
The most prominent actions of insulin in vivo are concerned with the acute regulation of carbohydrate and lipid metabolism in
liver, muscle, and fat, whereas IGFs act on skeletal and other tissues
to promote growth, differentiation, and survival. The receptors for
insulin and IGFs, which mediate these effects (IR and IGFR), are also
structurally related and highly homologous, consisting of extracellular
-subunits responsible for ligand binding and transmembrane
-subunits possessing protein-tyrosine kinase activity, in a
disulphide linked
-
-
-
configuration (1-3). Within the
intracellular portion, the level of sequence identity between the
receptors is greatest in the tyrosine kinase domain (84%) and somewhat
less in the flanking juxtamembrane and carboxyl-terminal regions (61 and 44%, respectively). Not surprisingly, the signaling mechanisms of
the insulin receptor (IR) and IGF-I receptor (IGFR) are broadly
similar. Ligand binding activates tyrosine kinase activity, leading to
phosphorylation of intracellular substrates, such as IRS and Shc
proteins, and the recruitment and/or stimulation of signal transducing
molecules, including phosphoinositide 3-kinase (PI 3-kinase) and
Grb2·Sos (4, 5). These signal transducers in turn promote activation
of protein-serine kinase cascades involving
phosphoinositide-dependent kinase/PKB and MAPK/Erk
kinase/MAPK, respectively, which modulate the activity of glucose
transporters, enzymes, and transcription factors (6, 7).
Given the similarity in structure and signaling mechanism of the
respective receptors, obvious questions arise concerning the basis of
specificity in the actions of insulin and IGFs in vivo. In
part, this specificity must reflect the different patterns of
expression of receptors and responsive pathways in different cell
types. Indeed, when examined in the same cell background, insulin and
IGFs induce the same end point responses (8-10). However, such studies
do not rule out the possibility of subtle differences in the coupling
of the receptors to different responses, and there are various problems
of interpretation in making detailed comparisons of IR and IGFR
activity in a given cell type. First, neither receptor is completely
specific for its ligand, and at high ligand concentrations, some
cross-reaction with the heterologous receptor is inevitable. Second, it
is difficult to make comparisons at equivalent occupancy of IR and IGFR
because of differences in ligand affinity and levels of expression.
Third, in cells that express both IR and IGFR a substantial fraction of
receptors assemble as hybrid structures capable of binding both ligands
(11). Finally, attempts to overcome these problems by overexpression of
receptors in transfected cells might distort the signaling specificity,
which could be seen at lower and more physiological levels of receptor expression.
In order to circumvent such problems, several laboratories have made
use of chimeric receptors, in which the intracellular domains of the
IR, IGFR, or insulin receptor-related receptor are coupled to a common
extracellular ligand binding domain (12-15). It was reported that the
IGFR was more efficient than the IR in mediating stimulation of DNA
synthesis in NIH3T3 fibroblasts, with no difference in stimulation of
glucose uptake (12). In contrast, in 3T3-L1 fibroblasts we found that
the IR mediated a greater stimulation of glycogen synthesis compared
with the IGFR, with no difference in the extent or efficiency of
stimulation of DNA synthesis (14). Other work with truncated receptors, site-directed mutants, and chimeras has suggested that the efficiency of "metabolic" and "mitogenic" stimulations may depend on the carboxyl-terminal domains of the respective receptors (16-20), although the results have not been entirely consistent (21). A serious
limitation of all these studies is that they have been carried out in
cultured fibroblasts that display only a limited range of rather small
responses to insulin and IGF-I compared with physiologically important
target tissues. We have therefore examined the question of intrinsic
signaling specificity by expressing IR and IGFR chimeras in
differentiated 3T3-L1 adipocytes, which are highly insulin-responsive.
We show here that glucose uptake is stimulated to a greater extent by
IR than IGFR and that differences in the relative phosphorylation of
distinct intracellular substrates by the IR and IGFR tyrosine kinases
contribute to signaling specificity of the two receptors.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Antibodies were obtained from TCB (mouse
monoclonal anti-phosphotyrosine, 4G10), Sigma (mouse monoclonal
anti-phosphotyrosine PY20), Promega (rabbit anti-ActiveTM
MAPK) or New England Biolabs (rabbit anti-phosphoAkt[Ser-473] and
rabbit anti-pp70S6-kinase[Thr-389]). Other antibodies were produced
in-house in rabbits using bacterially expressed GST fusion proteins as
immunogens: anti-IR-carboxyl-terminal (carboxyl-terminal 98 amino acids
of human IR), anti-IGFR-carboxyl-terminal (carboxyl-terminal 106 amino
acids of human IGFR), anti-Shc (SH2-domain), anti-IRS-1 (carboxyl-terminal 236 amino acids of rat IRS-1), and anti-p85 (N-terminal SH2-domain). The anti-Grb2 antibody (mouse monoclonal) was
a gift from Dr. J. Schlessinger (New York University Medical Center),
rabbit anti-GLUT4 was a gift from Prof. G. Gould (University of
Glasgow), rabbit anti-GLUT1 was a gift from Prof. S. Baldwin (University of Leeds), and goat anti-PKB and anti-p70S6 kinase antibodies were gifts from Dr. D. Alessi (University of Dundee). The
TrkC cDNA and Fra-1 cDNA probes were gifts from Dr. J. M. Tavaré (University of Bristol). NT-3 was generously provided by
Dr. E. Brewster (Regeneron Pharmaceuticals). Tissue culture media were
purchased from Life Technologies, Inc., radiochemicals from Amersham
Pharmacia Biotech, restriction enzymes from New England Biolabs,
oligonucleotides from Genosys and other reagents from Sigma.
Construction of Chimeras--
Chimeras containing the
extracellular and transmembrane portions of the neurotrophin receptor
TrkC together with the intracellular portion of the human IR (TIR) or
IGFR (TIGR) were constructed as described previously (14). The chimeras
were expressed under the regulation of the elongation factor 1
promoter (a kind gift from Dr R. E. Lewis (Eppley Institute for
Research in Cancer, University of Nebraska)) in the vector pcDNA3 (Invitrogen).
Tissue Culture--
3T3-L1 fibroblasts (ATCC) were maintained at
no higher than 70% confluency in DMEM containing 10% newborn calf
serum, 4.5 g/liter glucose, 2 mM glutamine, and antibiotics
(DMEM/newborn calf serum). For differentiation they were grown 2 days
postconfluency in the same medium and then for 2 days in medium
containing fetal calf serum instead of newborn calf serum (DMEM/fetal
calf serum) supplemented with insulin (5 µg/ml), dexamethasone (0.1 µg/ml), and isobutylmethylxanthine (110 µg/ml), for 2 days in
DMEM/fetal calf serum with insulin only and finally for 6 days in
DMEM/fetal calf serum. Differentiated cells were used only when at
least 90% of the cells showed adipocyte phenotype by accumulation of lipid droplets. 3T3-L1 fibroblasts were transfected using
LipofectAMINETM reagent (Life Technologies, Inc.) and
selected in medium containing 600 µg/ml G418 (Life Technologies,
Inc.) to produce stable expressing clones (obtained by subculturing at
limiting dilution on microtitre plates).
NT-3 Binding--
The expression levels of the chimeras in
3T3-L1 cells were analyzed by radioligand binding assay. NT-3 was
radioiodinated as described (14). The cells were incubated with
125I-NT-3 (30,000 dpm) and increasing concentrations of
unlabeled NT-3 in binding buffer (100 mM Hepes, 120 mM NaCl, 1 mM EDTA, 15 mM
NaC2H4O2) overnight at 4 °C,
washed twice in cold phosphate-buffered saline, solubilized in 0.1 M NaOH and counted in a NE1600 gamma counter.
IC50 values were obtained from calculations with
GraphPad PRISM, version 2.01.
Western Blotting--
Serum-starved adipocytes were stimulated
for 5 min and solubilized in lysis buffer (50 mM Hepes, 150 mM NaCl, 1 mM EDTA, 30 mM NaF, 1%
Triton X-100, 1 mM Na3VO4, 10 mM Na2P2O7, 0.1 mM 4-(2-aminoethyl)benzene sulfonyl fluoride, HCl, 2.5 mM benzamidine, 1 µg/ml antipain, 1 µg/ml leupeptin, 1 µg/ml pepstatin A), and the lysate was clarified by centrifugation at
13,500 × g for 15 min at 4 °C. Lysates were subjected to immunoprecipitation using anti-IRS-1 (1:200) or anti-Shc (1:200) antibodies plus protein A-agarose (2 mg/sample), and
immunoprecipitates were washed once in lysis buffer and twice in
phosphate-buffered saline on ice. Crude cell extracts or specific
immunoprecipitates were resolved by SDS-PAGE before electroblotting to
polyvinylidene difluoride membranes (Millipore), and specific proteins
were detected by incubation with appropriate antibodies in TBST (150 mM NaCl, 50 mM Tris, 0.1% Tween 20) after
blocking in 1% bovine serum albumin, followed by
125I-labeled secondary antibodies (approximately 0.2 µCi
per blot), and quantified on a Fujix BAS2000 phosphorimager.
Glucose Uptake--
Assays were performed as described
previously (22). In short, differentiated adipocytes in six-well plates
were serum-starved for 2 h in DMEM containing 25 mM
glucose and 2 mM glutamine and incubated in 1 ml of KRH
(136 mM NaCl, 4.7 mM KCl, 1.25 mM
CaCl2, 1.25 mM MgSO4, 10 mM Hepes, pH 7.4) with hormone at 37 °C for 30 min and
2-deoxy-D-[2,6-3H]glucose (0.33 µCi/ml;
final specific activity, 6.7 µCi/µmol) for an additional 5 min.
Uptake was stopped by three rapid washes on ice with KRH, the cells
were solubilized in 1 ml of 0.1 M NaOH and neutralized (50 µl of concentrated HCl), and radioactivity was determined by liquid
scintillation counting.
Plasma Membrane Lawn Assays of GLUT4 Translocation--
3T3-L1
adipocytes, grown on collagen-coated glass coverslips, were
serum-starved for 2 h. Cells were either left untreated or
stimulated for 15 min with 100 nM insulin or 4 nM NT-3. Coverslips were rapidly washed in ice-cold buffer
for the preparation of plasma membrane lawns exactly as described (23).
After fixation in paraformaldehyde, plasma membrane lawns were
incubated with either anti-GLUT4 or anti-GLUT1 antibody (1:100
dilution) for 2 h at room temperature. After washing, the
coverslips were incubated with fluorescein isothiocyanate-conjugated
donkey anti-rabbit IgG, washed, and mounted on glass slides. Coverslips
were viewed using a × 60 objective lens on a Nikon
Optiphot-2/Bio-Rad MRC-1000 microscope operated in laser scanning
confocal mode. Samples were illuminated at 488 nm, and images were
collected at 510 nm. Duplicate coverslips were prepared at each
experimental condition, and five random images of plasma membrane lawn
were collected from each. Five fields from each image were quantified
using Bio-Rad MRC-1000 confocal microscope operating software (CoMOS,
version 6.05.8), on an AST premmia SE P/60 personal computer.
Glycogen Synthesis--
Assays were performed as described
previously (24). In short, fully differentiated adipocytes in six-well
plates were serum-starved for 3 h in DMEM with 5.5 mM
glucose and 2 mM glutamine, stimulated with hormone for 30 min, and incubated with D-[U-14C]glucose (1 µCi/ml; final specific activity, 0.18 µCi/µmol) for 30 min.
Incubations were stopped by three rapid washes on ice with
phosphate-buffered saline, the cells were solubilized in 1 ml of 0.1 M NaOH, carrier glycogen was added (2 mg), and the samples
were boiled for 30 min. Glycogen was precipitated with 70% ethanol
overnight at
20 °C; the samples were centrifuged at 1720 × g, washed once with 70% ethanol, and resuspended in water;
and radioactivity was determined by scintillation counting.
Glycogen Synthase Activity Assay--
Assays were performed as
described (25). In short, differentiated adipocytes in six-well plates
were starved for 3 h in serum-free DMEM without glucose
supplemented with 20 mM Hepes and 1% bovine serum albumin,
incubated with hormone for 30 min, washed in 100 mM NaF-10
mM EDTA, scraped off, and sonicated. The enzyme activity
was determined in a Tris (50 mM), NaF (25 mM), EDTA (20 mM) buffer with glycogen (10 mg/ml) and
uridine-5'-diphospho-D-[U-14C]glucose (5 µCi/ml; final specific activity, 1.3 µCi/mg) and in the absence or
presence of glucose 6-phosphate (2 mg/ml) for 20 min at 30 °C. The
samples were spotted on filter paper and washed three times in 70%
ethanol and dried, and radioactivity was determined by liquid
scintillation counting. Activity was calculated as a percentage of the
maximum: that is, 100 × (activity without glucose
6-phosphate)/(activity with glucose 6-phosphate).
Phosphoinositide 3-Kinase Assay--
Cells were stimulated for 5 min, lysed, and immunoprecipitated with either anti-IRS-1 (1:200) or
anti-phosphotyrosine PY20 (1:50) antibody. The immunoprecipitates were
washed and assayed as previously described (26). In short, the
immunoprecipitates were incubated with phosphatidylinositol and
[32P]ATP for 15 min at 37 °C, and the reaction was
stopped with chloroform:methanol (1:2). The lipids were extracted twice
by acidic chloroform extraction, and the lower phase was collected and
dried in a speed-vacuum drier. The lipid film was resuspended and
spotted on TLC plates (kieselgel 60F254 from Merck) and run in
chloroform:methanol:ammonia:water (300:210:45:75 (v/v)). The
resolved radiolabeled phosphatidylinositol 3-phosphate was quantified
on a Fujix BAS2000 phosphorimager.
PKB Kinase Activity--
The assay was performed as described
(27). Cells were serum-starved overnight, stimulated with hormone for 5 min, and extracted in PKB lysis buffer (50 mM Tris, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM sodium orthovanadate, 50 mM NaF, 5 mM pyrophosphate, 0.27 M sucrose, 1 µM microcystin, 0.1%
-mercaptoethanol, protease inhibitors). The extracts (250 µg) were immunoprecipitated with PKB-
-specific antibody followed by PKB-
-specific antibody or PKB-
-specific antibody (all at 5 µg/sample) and protein
G-Sepharose (2 mg), and the precipitates were washed twice in lysis
buffer with 0.5 M NaCl and once in Buffer A (50 mM Tris, 0.1 mM EGTA, 0.1%
-mercaptoethanol). The kinase activity was measured against cross-tide substrate in assay buffer (50 mM Tris, 0.1 mM EGTA, 2.5 µM PKI, 0.1 mM ATP,
10 mM MgCl2, 300 µM cross-tide)
with [32P]ATP (0.3 µCi/sample) for 30 min at 30 °C.
Incubations were stopped by spotting on p81 Whatman filter paper and
washing in phosphoric acid (85 mM); the papers were washed
three additional times, dipped in acetone, and dried; and radioactivity
was determined by scintillation counting.
Phosphorylation of PKB, p70S6-Kinase, and MAP Kinase--
The
serine phosphorylation of PKB/Akt (
- and
-isoforms) after 5 min
of stimulation was determined by Western blotting (as described above)
with antibody specific for the phosphorylated (Ser-473) form of the
enzyme (rabbit anti-phosphoAkt[Ser473] from Upstate Biotechnology,
Inc.). The phosphorylation of MAPK was similarly determined by blotting
with an antibody specific for the doubly phosphorylated (Thr/Tyr) form
of the enzyme (rabbit anti-ActiveTM MAPK from Promega). The
phosphorylation of p70S6-kinase after 15 min of stimulation was
determined by immunoprecipitation of clarified lysates with
goat-anti-p70S6-kinase (1 µg/sample) and protein G-agarose (20 µg/sample), followed by SDS-PAGE and Western blotting with an
antibody specific for the phosphorylated form of the enzyme (rabbit
anti-pp70S6-kinase[Thr-389] from New England Biolabs). Blotting data
were quantified on a Fujix BAS2000 phosphorimager.
Induction of Fra-1 mRNA--
Fully differentiated 3T3-L1
adipocytes were serum-starved overnight and stimulated for 4 h
with hormone, and RNA was extracted with TriReagent (Sigma). Northern
blots were performed as described (28), transferred to
HybondTM N membrane (Amersham Pharmacia Biotech), and
cross-linked by UV irradiation. Probe for Fra-1 (generously provided by
Dr. J. M. Tavaré, University of Bristol) was labeled
according to the protocol with [32P]CTP using Rediprime
labeling system (Amersham Pharmacia Biotech) and purified on
NickTM columns (Amersham Pharmacia Biotech). The membranes
were incubated in QuickHyb (Stratagene) for 1 h at 68 °C with
the boiled probe and washed twice in 2× SSC (1× SSC: 0.15 M NaCl, 15 mM sodium citrate) with 0.1% SDS at
room temperature and twice in 0.5× SSC with 0.1% SDS at 65 °C. The
later samples were analyzed by dot blots after verification of the
probe specificity on Northern blots. The results were quantified on a
Fujix BAS2000 phosphorimager.
 |
RESULTS |
Expression of TIR and TIGR Constructs--
Chimeric constructs
containing the intracellular portions of the IR or IGFR together with
the extracellular portion of the TrkC receptor (TIR and TIGR,
respectively) were expressed in 3T3-L1 cells under the control of the
elongation factor 1
promoter, which was found to drive similar
levels of expression in both fibroblasts and adipocytes. Clonal lines
of transfected fibroblasts were selected with G418 and screened for
expression of chimeras by Western blotting cell extracts with anti-IR
and anti-IGFR antibodies as appropriate, no suitable anti-TrkC antibody
being available. Following differentiation into adipocytes, clones were
rescreened by Western blotting of extracts with anti-phosphotyrosine
antibodies after stimulation with NT-3 or insulin. Two clones were
selected for further study that expressed similar levels of TIR and
TIGR, as judged by relative intensity of NT-3-stimulated
autophosphorylation in adipocytes (Fig. 1
and Table I). The levels of expression were reproducible on repeated differentiation of adipocytes from fibroblast stocks. The levels of expression of chimeras were
approximately 2-fold (Table I) higher than those of endogenous insulin
receptors, as judged by Western blotting with anti-IR and/or
anti-phosphotyrosine antibodies after stimulation with NT-3 or insulin.
By the same criteria, the levels of endogenous insulin receptors were
identical in both clones. There was no evidence of
cross-phosphorylation of chimeras following stimulation with insulin or
of insulin receptors following stimulation with NT-3. Radioligand
binding assays were carried out on the selected clones to verify that
the chimeras bound NT-3 with an affinity comparable to the wild-type
TrkC (Fig. 1C). There was no detectable binding of NT-3 to
untransfected adipocytes.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of chimeras in 3T3-L1
adipocytes. A, anti-phosphotyrosine Western blotting.
Serum-starved cells were stimulated for 5 min with 4 nM
NT-3 (N) or 10 nM insulin (I) or left
unstimulated (O) and lysed, and 100 µg of protein from
each lysate was subjected to SDS-PAGE in duplicate and immunoblotted
with anti-phosphotyrosine antibody (4G10). B, time course of
receptor autophosphorylation. Anti-phosphotyrosine blots obtained as in
A were quantified by phosphorimaging. C, NT-3
binding. Cells grown in 24-well plates were incubated in duplicate with
125I-NT-3 and the indicated concentrations of unlabeled
NT-3 at 4 °C overnight and washed, and bound radioactivity was
counted. Filled circles, TIR; open circles, TIGR;
triangles, untransfected 3T3 L1 adipocytes;
crosses, TrkC-transfected CHO cells (MG86). Estimated
IC50 values are as follows: TIR, 0.14 nM; TIGR,
0.10 nM; TrkC, 0.14 nM.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Receptor levels in 3T3-L1 adipocytes of chimeric expressing clones
Lysates from clonal cell lines that had been stimulated with 10 nM insulin or 4 nM NT-3, containing equivalent
amounts of protein, were subjected to SDS-PAGE and Western blotting.
|
|
Metabolic Responses in 3T3-L1 Adipocytes--
Previous work on
3T3-L1 fibroblasts had shown that TIR mediated a greater stimulation of
glycogen synthesis than TIGR, although the magnitude of response to
NT-3 or insulin in these cells was relatively small (14). The present
studies were conducted with an independently derived set of clones, in
which expression of chimeras was under the control of a different
promoter from that used previously. We tested metabolic responses
following stimulation of TrkC chimeras in 3T3-L1 adipocytes, which
express the GLUT4 glucose transporter and are much more
insulin-responsive than fibroblasts.
Glucose uptake was stimulated similarly (typically 6-8-fold) by 10 nM-insulin in both clones of transfected cells. However, when cells were treated with NT-3, stimulation of glucose uptake was
consistently 2-fold greater via TIR than via TIGR, at all concentrations of NT-3 (Fig.
2A). There was no detectable
response to NT-3 in untransfected cells.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
Stimulation of glucose uptake and glycogen
synthesis. A, 2-deoxy-glucose uptake. Cells grown in
six-well plates were serum-starved for 2 h and stimulated for 30 min with the indicated concentrations of NT-3 (O,
unstimulated; N, 4 nM NT-3) before measurement
of 2-deoxyglucose uptake over 5 min as described under "Experimental
Procedures." Data are means ± SD from three (dose-response) or
five (inserted bars) independent experiments performed in duplicate,
normalized to stimulation with 10 nM-insulin (mean insulin
responses, 3635 cpm/well for TIR and 4265 cpm/well for TIGR).
Filled circles and filled columns, TIR;
open circles and open columns, TIGR
(*p < 0.05, TIR versus TIGR). B,
glycogen synthesis. Cells grown in six-well plates were serum-starved
for 3 h and stimulated for 30 min with the indicated
concentrations of NT-3 (O, unstimulated; N, 4 nM NT-3) before measurement of [14C]glucose
incorporation into glycogen over 90 min as described under
"Experimental Procedures." Data are means ± SD from three
(data points) or five (columns) independent
experiments performed in duplicate, normalized to stimulation with 10 nM-insulin (mean insulin responses, 18,450 cpm/well for TIR
and 18,900 cpm/well for TIGR). Symbols as in A. C, glycogen
synthase activity. Cells grown in six-well plates were serum-starved
for 3 h and stimulated for 30 min without (hatched
columns) or with (gray columns) NT-3 (4 nM)
before measurement of glycogen synthase fractional activity (with or
without glucose 6-phosphate) as described under "Experimental
Procedures." Data are means ± SD from six (TIR) or three (TIGR)
independent experiments performed in duplicate, normalized to activity
with 10 nM-insulin (mean insulin responses, 11.7% in TIR
and 9.85% in TIGR). Differences between values for TIR and
corresponding values for TIGR were not significant (p > 0.1).
|
|
To confirm that the stimulation of glucose uptake by the two chimeras
reflected primarily the translocation of GLUT4 glucose transporters to
the plasma membrane, we performed plasma membrane lawn assays. Plasma
membrane lawns from disrupted cells were probed with anti-GLUT4 or
GLUT1 antibody followed by immunofluorescence detection (Fig.
3). In all cell lines (TIR, TIGR, and
untransfected), insulin induced 4-5-fold increases in GLUT4
immunostaining, but only 1.5-2-fold increases in GLUT1 immunostaining.
In agreement with the results on glucose uptake, the TIR chimera
mediated a significantly greater increase in GLUT4 at the plasma
membrane than the TIGR chimera (Fig. 3B). There was no
effect of NT-3 on GLUT4 distribution in untransfected cells lacking
chimera. Similar trends were apparent for the translocation of GLUT1 in
TIR and TIGR cells, although the small magnitude of stimulations made it difficult to draw clear conclusions in this case.

View larger version (92K):
[in this window]
[in a new window]
|
Fig. 3.
Plasma membrane lawn assay of GLUT4 and GLUT1
translocation. Serum-starved 3T3-L1 adipocytes were either left
untreated (O) or stimulated with 100 nM insulin
or 4 nM NT-3 (N) for 15 min before preparation
of plasma membrane lawns and assay of glucose transporter
translocation. Data from each experiment, utilizing 50 fields for each
condition, were quantified as described under "Experimental
Procedures." A, representative images from a typical
experiment. B, GLUT4 at plasma membrane (PM),
calculated as mean ± S.E. fold increase over basal for three
(wild-type untransfected 3T3-L1 adipocytes (WT)), five
(TIR), and four (TIGR) independent experiments. C, GLUT1 at
plasma membrane, calculated as mean ± S.E. fold increase over
basal for three independent experiments. Statistically significant
differences between responses to NT-3 in TIR and TIGR cells are
indicated.
|
|
Incorporation of glucose into glycogen was stimulated approximately
15-fold by insulin in both clones. Maximum stimulation of glycogen
synthesis and glycogen synthase by 4 nM NT-3 was similar in
TIR and TIGR cells (Fig. 2, B and C), but TIR
cells responded significantly better than TIGR at submaximal NT-3
concentrations (Fig. 2B). Again, stimulation of glycogen
synthesis by NT-3 was undetectable in untransfected cells. The fact
that the difference in maximum stimulation of glucose uptake by NT-3 in
TIR and TIGR cells was not reflected in differential maximal
stimulation of glucose incorporation into glycogen suggests that
glycogen synthase activity, rather than glucose transport, was
rate-limiting for glycogen synthesis under these conditions.
Consistent with this hypothesis, glycogen synthesis was near maximally
stimulated at concentrations of NT-3 that produced little stimulation
of glucose uptake. Moreover, glycogen synthesis was similarly more
sensitive than glucose uptake to stimulation by insulin (data not shown).
Phosphorylation of Intracellular Substrates--
The initial step
in signal transduction from the IR and IGFR is the tyrosine
phosphorylation of intracellular substrates, such as IRS and Shc
proteins, which then recruit other signaling intermediates, such as PI
3-kinase and Grb2·Sos, respectively (4, 29). Substantial evidence
implicates the PI 3-kinase pathway as an essential component of
signaling to glucose transport and glycogen synthesis (30), whereas
Grb2·Sos is required for activation of the MAP kinase pathway (7). To
examine whether the differences in metabolic responses mediated by TIR
and TIGR in 3T3-L1 adipocytes were a consequence of differential
activation of known signaling pathways, we used sequential
immunoprecipitation and Western blotting to determine the tyrosine
phosphorylation of IRS-1 and Shc and the association of these proteins
with the p85 regulatory subunit of PI 3-kinase and Grb2, respectively
(Fig. 4). Data were normalized by
expression as a percentage of signals obtained following stimulation
with 10 nM insulin, which produced similar responses in
both clonal lines.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 4.
Phosphorylation and SH2-association of IRS-1
and Shc. A, IRS-1 tyrosine phosphorylation.
Serum-starved cells were stimulated for 5 min with NT-3 or insulin as
indicated and lysed, and 500 µg of protein was immunoprecipitated
with anti-IRS-1 antibody and subjected to SDS-PAGE and immunoblotting
with anti-phosphotyrosine antibody. A representative gel is shown with
each data set, and numerical data shown are means ± SD obtained
by quantification of gels from three independent experiments performed
in duplicate, normalized to stimulation with 10 nM insulin
(mean insulin responses, 110 arbitrary phosphorimager units for TIR and
145 units for TIGR). Filled circles, TIR; open
circles, TIGR; *p < 0.05, TIR versus
TIGR. B, IRS-1 association with p85 regulatory subunit of PI
3-kinase. Lysates from stimulated cells were prepared,
immunoprecipitated and electrophoresed as in A before
immunoblotting with anti-p85 antibody. Data presentation is as in
A (mean insulin responses, 320 arbitrary phosphorimager
units in TIR and 400 units in TIGR). C, Shc tyrosine
phosphorylation. Lysates from stimulated cells were prepared as in
A, immunoprecipitated with anti-Shc antibody, and
electrophoresed and immunoblotted with anti-phosphotyrosine antibody.
Data presentation is as in A (mean insulin responses, 174 arbitrary phosphorimager units in TIR and 144 units in TIGR).
D, Shc association with Grb2. Lysates from stimulated cells
were prepared, immunoprecipitated, and electrophoresed as in
C before immunoblotting with anti-Grb2 antibody. Data
presentation is as in A (mean insulin responses, 515 arbitrary phosphorimager units in TIR and 450 units in TIGR).
|
|
The level of IRS-1 tyrosine phosphorylation induced by NT-3 after 5 min
was approximately 2-fold higher in TIR cells compared with TIGR, at all
concentrations (Fig. 4A). It was confirmed by stripping and
reprobing blots with anti-IRS antibody that equal amounts of IRS-1 were
immunoprecipitated from TIR and TIGR cells. The level of p85 in the
same IRS-1 immunoprecipitates was higher in TIR cells than TIGR,
although the basal was also higher (Fig. 4B). The
differences in stimulation of IRS-1 phosphorylation and p85 association
were maintained throughout the 30-min period used to measure glucose
uptake (Fig. 5). Thus, the relative
NT-3-induced IRS-1 phosphorylation and p85 association mediated by TIR
and TIGR closely paralleled stimulation of glucose uptake.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
Persistence of IRS-1 phosphorylation and p85
association. IRS-1 tyrosine phosphorylation and association with
p85 were determined after 30 min of incubation without (0)
or with (N) 4 nM NT-3, as described in legend to
Fig. 4. Data were calculated relative to the effect of 10 nM insulin for three independent experiments, as in Fig. 4.
Filled columns, TIR; open columns,
TIGR.
|
|
In contrast, NT-3-induced tyrosine phosphorylation of the 52-kDa
isoform of Shc, and its association with Grb2, were each approximately
2.5-fold higher in TIGR cells compared with TIR (Fig. 4,
C and D). Weak stimulation of phosphorylation of
the 66-kDa isoform of Shc was seen in TIGR but not TIR cells (Fig. 4C).
Activation of Phosphoinositide 3-Kinase--
We next examined
whether differences in p85 association with IRS-1 were paralleled by
differences in PI 3-kinase activity in anti-IRS-1,
anti-phosphotyrosine, and anti-p85 immunoprecipitates. There was no
stimulation of PI 3-kinase activity by NT-3 in anti-IRS-1 or
anti-phosphotyrosine immunoprecipitates in untransfected cells. Activity of PI 3-kinase in anti-IRS-1 immunoprecipitates was
approximately 70% greater in TIR cells than in TIGR cells following
NT-3 stimulation (Fig. 6A). As
with the other differential responses, the maximum stimulation by NT-3
was somewhat greater than that with 10 nM insulin in TIR
cells, but appreciably less in TIGR cells. No significant difference
was observed in the PI 3-kinase activities in anti-phosphotyrosine precipitates from NT-3-stimulated TIR and TIGR cells (Fig.
6B). The maximum activity in response to NT-3 was very
similar to the response to 10 nM insulin in both cell lines
and approximately 30% of the maximum PI 3-kinase activity observed in
anti-IRS-1 immunoprecipitates. As previously observed (26), PI 3-kinase activity in anti-p85 precipitates was not significantly stimulated by
insulin, nor was it stimulated by NT-3, but the activities measured
were the same in TIR and TIGR cells (data not shown). Only
approximately 20% of the p85 precipitable PI 3-kinase activity was
recovered in IRS-1 precipitates from insulin-stimulated TIGR cells.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 6.
Activation of PI 3-kinase. A,
PI 3-kinase activity in anti-IRS-1 immunoprecipitates. Serum-starved
cells were stimulated for 5 min with NT-3 as indicated (O,
unstimulated; N, 4 nM NT-3) and lysed, and 100 µg of protein was immunoprecipitated with anti-IRS-1 antibody before
measurement of PI 3-kinase activity as described under "Experimental
Procedures." Data are means ± range/SD from two (data
points) or four (columns) independent experiments
performed in duplicate, normalized to stimulation with 10 nM-insulin (mean insulin responses, 1130 arbitrary
phosphorimager units in TIR and 1280 units in TIGR). Filled
circles and filled columns, TIR; open
circles and open columns, TIGR; (*p < 0.05, TIR versus TIGR). B, PI 3-kinase activity
in anti-phosphotyrosine immunoprecipitates. Cells were treated and
extracted as in A except that immunoprecipitation was
carried out with anti-phosphotyrosine antibody prior to determination
of PI 3-kinase activity. Data presentation and symbols are as in
A (mean insulin responses, 450 arbitrary phosphorimager
units in TIR and 390 units in TIGR).
|
|
Activation of Akt/PKB--
Recent evidence has indicated that
signaling downstream from PI 3-kinase involves translocation and/or
activation of one or more phosphoinositide-dependent
kinases, which in turn phosphorylate and activate Akt/PKB, a
serine/threonine-specific protein kinase that exists in three isoforms
,
, and
(6). The three isoforms were present at similar
levels in 3T3-L1 adipocytes, as reflected in the basal or
insulin-stimulated kinase activity measured in specific
immunoprecipitates (Fig. 7). In both TIR
and TIGR-expressing cells, NT-3 (4 nM) induced levels of
kinase activity of all three isoforms that were approximately the same
as those induced by insulin (10 nM) (all 2-3 fold over
basal), with no significant difference between the two chimeras. We
also assessed the phosphorylation of Ser-473 of PKB (
- and
-isoforms) by Western blotting with phosphopeptide-specific
antibody, as an index of stimulation (6). Again, NT-3 and insulin
induced similar levels of phosphorylation (6-fold over basal), with no
significant difference between TIR or TIGR cells at either 5 or 30 min
of stimulation (Fig. 8A).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 7.
Activation of protein kinase B. Serum-starved cells were stimulated for 5 min with 4 nM
NT-3 (N) or 10 nM insulin (I) or left
unstimulated (O) and lysed, and 200 µg of protein from
each lysate was immunoprecipitated with antibodies specific for the
-, -, or -isoform of PKB before assaying PKB activity as
described under "Experimental Procedures." Data are means ± SD from three independent experiments performed in duplicate,
normalized to stimulation of the -isoform with 10 nM-insulin ( , 494 cpm/mg protein in TIR and 398 in
TIGR). Filled columns, TIR; open columns,
TIGR.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
Phosphorylation of PKB, p70S6 kinase, and MAP
kinase. A, phosphorylation of PKB on Ser-473.
Serum-starved cells were stimulated for 5 or 30 min as in Fig. 7, and
lysates were subjected to SDS-PAGE and immunoblotted with antibody
specific for the phospho-S473 form of PKB (isoforms and ). Data
are means ± SD from three independent experiments performed in
duplicate, normalized to stimulation with 10 nM-insulin.
B, phosphorylation of p70S6-kinase on Thr-389. Serum-starved
cells were stimulated for 15 min as indicated, and lysates were
immunoprecipitated with anti-p70S6-kinase antibody, subjected to
SDS-PAGE, and immunoblotted with antibody specific for the phospho-Thr
389 form of the p70S6 kinase. Data are means ± SD from four
independent experiments performed in duplicate, normalized to
stimulation with 10 nM-insulin. C,
phosphorylation of 42-kDa MAPK. Serum-starved cells were stimulated for
5 min with NT-3 as indicated, and lysates were subjected to SDS-PAGE
and immunoblotted with antibody specific for the doubly (Thr/Tyr)
phosphorylated form of MAPK. Data are mean ± range from two
independent experiments performed in duplicate, normalized to
stimulation with 10 nM-insulin (**p < 0.005 TIGR versus TIR). In all panels, filled
columns represent TIR, and open columns represent
TIGR.
|
|
Phosphorylation of p70S6 Kinase--
Activation of p70S6 kinase
is, like the activation of PKB, dependent on PI 3-kinase (30).
Stimulation of glucose transport by insulin is clearly independent of
p70S6 kinase activity, but the enzyme may play a role in the activation
of glycogen synthase in some cell types including 3T3-L1 adipocytes
(31). Activation of p70S6 kinase by growth factors is associated with
phosphorylation at multiple sites, of which Thr-412 in the mouse enzyme
(corresponding to Thr-389 in the human enzyme) correlates most closely
with activity (32). We used a phospho-specific antibody to determine
phosphorylation of p70S6 kinase in TIR or TIGR cells after 15 min of
stimulation with NT-3 or insulin (Fig. 8B). The two chimeras
were equally effective in mediating p70S6 kinase phosphorylation, at
both submaximal and maximal concentrations of NT-3, and the stimulation
at the higher concentration of NT-3 was very similar to that induced by insulin.
Phosphorylation of MAP Kinase--
Tyrosine phosphorylation of Shc
and its association with the Grb2·Sos complex is a major pathway
leading via Ras, Raf, and MAPK/Erk kinase to the phosphorylation and
activation of MAP kinase (7). This pathway has been implicated in
signaling to transcriptional and mitogenic events, but it appears not
to be important in regulating acute metabolic responses (7). We
investigated the activity of MAP kinase by immunoblotting cell extracts
with an antibody specific for the doubly (Thr/Tyr) phosphorylated and
hence activated form of the enzyme (33). In 3T3-L1 cells, the p42
isoform of MAP kinase was more abundant than p44 isoform, as judged by
immunoblotting with a pan-specific anti-MAP kinase antibody, or with
anti-phospho-MAP kinase in stimulated cells (data not shown).
Phosphorylation of p42MAPK in response to a maximally
effective concentration of NT-3 (4 nM) was consistently and
significantly greater in TIGR cells than in TIR cells (Fig.
8C). The response to NT-3 in TIGR cells was also greater
than the response to insulin. Similar differences were evident with
p44MAPK (data not shown).
Induction of Fra-1 mRNA--
Fos-related antigen 1 (Fra-1) is
a nontransforming Fos analogue involved in G0 to
G1 transition and asynchronous cell growth. Fra-1 mRNA
is induced by insulin or serum (34). Because measurement of
mitogenesis/DNA synthesis is not meaningful in terminally
differentiated 3T3-L1 cells, which do not divide, we used induction of
Fra-1 mRNA as an alternative end point readout of the MAPK pathway. We found no difference between TIR or TIGR cells, both of which showed
4-5-fold induction of Fra-1 mRNA after 4 h of incubation with
4 nM NT-3, similar to the response to 10 nM
insulin (data not shown).
 |
DISCUSSION |
Although insulin and IGFs exert distinct physiological effects
in vivo, the contribution of differences in receptor
function, as opposed to receptor distribution, to this specificity
remains unclear. Functional differences might arise from the kinetics of ligand association and dissociation, affecting the lifetime and/or
intracellular itinerary of the activated receptors (35, 36).
Alternatively, the receptor intracellular domains might possess
different signaling capacities, reflecting their differences in primary
sequence (nonidentity, 16% in the tyrosine kinase domain, 39% in the
juxtamembrane domain, and 56% in the carboxyl-terminal domain). To
focus on the activity of intracellular domains without interference
from endogenous receptors and to allow examination of a range of
physiologically relevant metabolic responses, we expressed TrkC-IR
(TIR) or TrkC-IGFR (TIGR) chimeras in 3T3-L1 adipocytes. Signaling
capacities of the IR and IGFR have previously been compared only in
transfected fibroblasts, in which reaction of ligands with endogenous
as well as transfected receptors complicates interpretation of data,
and the spectrum and magnitude of metabolic responses are rather small;
the results of such studies have been inconsistent. For instance, it
was reported that the IGFR was more effective than the IR in
stimulating DNA synthesis and MAP kinase activity (12, 37), although in
other work, no such difference was observed (14, 38). The IR appeared
to be more effective than IGFR in phosphorylating IRS-1 and activating
PI 3-kinase in one study (38) but not in another (39).
We found that stimulation of glucose uptake and GLUT4 translocation in
3T3-L1 adipocytes was more effectively mediated by TIR than TIGR (Figs.
2 and 3). TIR also mediated greater stimulation of IRS-1
phosphorylation and IRS-1-associated PI 3-kinase activity at both early
and late time points (Figs. 4-6). These differences were consistently
observed when paired clones of 3T3-L1 fibroblasts, selected for similar
levels of expression of TIR and TIGR, were differentiated on multiple
occasions. The differences were not a consequence of unequal or
excessive expression of the respective chimeras, as if anything, the
TIGR was expressed at a slightly higher level than TIR in the
differentiated adipocytes, and the level of expression of both chimeras
was of the same order as that of endogenous insulin receptors. We also
rule out the possibility that the different responses of TIR and TIGR
cells to NT-3 reflect chance clonal variation, as insulin acting via
its own receptor elicited very similar responses in both sets of cells.
Moreover, phosphorylation of Shc showed the opposite relationship to
phosphorylation of IRS-1 in the same cells, being more effectively
induced via the TIGR than via TIR (Fig. 4).
The more effective stimulation of glucose uptake via the IR than the
IGFR chimera was manifest as a difference in maximum response rather
than half-maximally effective concentration of NT-3 (EC50
approximately 0.2 nM), although the dose-response
relationships were not defined with sufficient precision to rule out a
difference in sensitivity. It is generally believed that glucose uptake
reflects the number of GLUT4 transporters at the plasma membrane (29), and we showed that the translocation of GLUT4 was indeed greater in
response to stimulation of TIR than TIGR (Fig. 3). This result implies
that the IR signals to a larger intracellular pool of transporters than
the IGFR, which might reflect differential efficiency of mobilization
from a single pool of transporters, or differential recruitment from
more than one pool. In relation to the latter possibility, it has been
shown that GLUT4 vesicles cycle through several distinct intracellular
compartments in adipocytes (40), and in skeletal muscle, discrete pools
of GLUT4 vesicles are responsive to stimulation by insulin and
contraction (41).
There is ample evidence that PI 3-kinase activity is both necessary and
sufficient for stimulation of glucose transport (29, 30). Differences
in glucose uptake and GLUT4 translocation mediated by TIR and TIGR were
paralleled by greater IRS-1-associated PI 3-kinase activity, and the
stimulations of glucose uptake and IRS-1 phosphorylation showed similar
NT-3 concentration dependence (EC50 approximately 0.2 nM) (Figs. 2-4). In contrast, TIR and TIGR induced similar
PI 3-kinase activity measured in anti-phosphotyrosine precipitates, and
this activity was increased at very low concentrations of NT-3 (<0.04
nM). Our finding that relative stimulations of glucose
transport correlate better with IRS-associated than with anti-phosphotyrosine-precipitable PI 3-kinase activity are at variance
with studies suggesting that IRS-1-associated PI 3-kinase was not
essential for glucose transport stimulation (42, 43).
The serine-specific protein kinase PKB/Akt has been identified as a
downstream effector of PI 3-kinase, which is activated by
phosphoinositide-dependent kinases secondarily to
recruitment of both PKB and phosphoinositide-dependent
kinase to membranes via association with the PI 3-kinase product
phosphatidylinositol 3,4,5 trisphosphate (6). Studies of the role of
PKB in stimulation of glucose transport have produced conflicting data.
On the one hand, glucose uptake was increased in 3T3-L1 cells
expressing constitutively active or inducible PKB (44-47). However,
expression of a dominant negative PKB failed to block
insulin-stimulated glucose uptake (48, 49). We found no difference in
levels of PKB activity in isoform-specific immunoprecipitates or in
phosphorylation of serine 473 at early and late time points, in TIR and
TIGR cells stimulated with NT-3 (Figs. 7 and 8), despite the
substantial difference in IRS-1-associated p85 and PI 3-kinase activity
at the same NT-3 concentration. It may be that a small activation of PI
3-kinase is sufficient for maximum activation of PKB or that the
IRS-1-associated pool of PI 3-kinase does not have as much influence on
PKB activity as the anti-phosphotyrosine-precipitable pool. Regardless
of the relationship between PKB and PI 3-kinase activities, our data
suggest that PKB activity alone is not the sole determinant of
stimulated glucose uptake, as identical PKB activities were observed in
TIR and TIGR cells exhibiting significantly different stimulations of
glucose uptake.
In contrast to the stimulation of glucose transport, incorporation of
glucose into glycogen was stimulated to the same maximum by NT-3 in TIR
and TIGR cells, although TIR cells were somewhat more responsive at low
NT-3 concentrations (EC50 values in the range of 0.01-0.03
nM) (Fig. 2). The disparity in NT-3 concentration dependence and fold stimulation of glycogen synthesis compared with
glucose uptake suggests that the stimulation of synthesis reflected
activation of glycogen synthase rather than increased glucose uptake.
The similar effectiveness of IR and IGFR in stimulating glycogen
synthesis in 3T3-L1 adipocytes contrasts with the substantial difference observed previously in 3T3-L1 fibroblasts (14). However, it
has been reported that the activation of glycogen synthase involves
predominantly inhibition of glycogen synthase kinase-3 in 3T3-L1
fibroblasts but stimulation of PP1 in adipocytes (50), and it may be
that this difference in mechanism underlies the difference in
responsiveness to IR and IGFR in the two cell types. Like the
stimulation of glucose uptake, activation of glycogen synthase requires
PI 3-kinase (30). In terms of NT-3 concentration dependence and
relative effectiveness of IR and IGFR, stimulation of glycogen
synthesis correlates better with anti-phosphotyrosine-precipitable than
IRS-1-associated PI 3-kinase activity, raising the possibility that
separate pools of PI 3-kinase are involved in stimulation of glucose
uptake and glycogen synthase. Certainly, the signaling pathways to
GLUT4 translocation and glycogen synthase activation appear to diverge
downstream of PI 3-kinase. PKB has been proposed as the principal route
to inactivation of glycogen synthase kinase-3, which in turn is thought
to be the major mechanism of activation of glycogen synthase in many
tissues (51). However, in 3T3-L1 adipocytes, levels of glycogen
synthase kinase-3 are low, and glycogen synthesis is not activated by
constitutively active PKB (44, 46). There is evidence that p70S6 kinase
contributes to activation of glycogen synthase in 3T3-L1 adipocytes
(31). Consistent with the similar stimulations of glycogen synthesis mediated by TIR and TIGR, we found no difference between the chimeras with respect to the activation of p70S6 kinase.
It seems clear, therefore, that the contribution of different signaling
pathways to end point responses may vary not only with respect to
different responses in a given cell but also with respect to a given
response in different cell types. Against this background, it is
difficult to predict relative efficiency of IR and IGFR in mediating
metabolic effects in other tissues based on the present data for
glucose transport in 3T3-L1 adipocytes. Interestingly, in hepatocytes,
as in 3T3-L1 fibroblasts, glycogen synthesis was more effectively
stimulated via IR than IGFR, although both receptors mediated similar
activation of PKB (52). The insulin-specific stimulation of glycogen
synthesis in hepatocytes appeared to involve a rapamycin-sensitive pathway.
It is not meaningful to study classical mitogenic responses
(proliferation/DNA synthesis) in a terminally differentiated and nondividing cell line such as the 3T3-L1 adipocyte. However, we examined various components of the MAP kinase pathway that have been
implicated in transcriptional and mitogenic responses in other cells
(7). TIGR cells were more responsive than TIR with regard to
stimulation of Shc phosphorylation, association of Shc with Grb2, and
activation of MAP kinase (Figs. 4 and 8). No difference was observed in
the induction of Fra1 mRNA in TIR and TIGR cells stimulated by a
near-maximal concentration of NT-3, although it is possible that
relatively modest activation of MAP kinase is sufficient for maximal
Fra1 induction and that a differential effect of TIGR and TIR on Fra1
mRNA might have been observed at lower NT-3 concentrations. Because
TIGR was expressed at a slightly higher level than TIR in the cell
lines studied, it cannot be definitely concluded that the IGFR is more
efficient than the IR in phosphorylating Shc. However, the relative Shc
responses do provide excellent controls for the IRS-1 phosphorylation
measured in the same cells, and the ratio of IRS/Shc phosphorylation
was approximately 4-fold higher in TIR cells than in TIGR cells across the full range of NT-3 concentrations tested.
Various mechanisms might contribute to relative specificity in
substrate phosphorylation by the IR and IGFR, including differences in
the intrinsic specificity of the tyrosine kinases themselves (53, 54),
differences in the association of substrates with receptors via PTB or
other domains (55-58), the modulation of such interactions by
receptor-specific adaptor proteins, such as Grb10 (59, 60), or
differences in endocytosis and subsequent trafficking of receptors (61,
62). No major differences between the two receptor kinases were
apparent in the phosphorylation of recombinant IRS-1 in
vitro (39), although this result does not exclude possible differences in activity of receptors toward IRS-1 in intact cells, where receptors and IRS-1 may be subject to regulatory phosphorylation on serine residues or modulation by other proteins. The
carboxyl-terminal domains of the IR and IGFR have been implicated in
signaling specificity (18-20), although the influence of this region
must be relatively subtle, as carboxyl-terminally truncated IR and IGFR
signal normally in at least some cell types (63, 64). Surprisingly, the
insulin receptor-related receptor, which is more similar to IGFR than to IR in its carboxyl-terminal domain, signaled with similar efficiency to the IR in fibroblasts and in 3T3-L1 cells (13). Further studies on
chimeric constructs involving exchange or mutagenesis of
carboxyl-terminal or other subdomains may help to define the residues
responsible for IR and IGFR signaling specificity.
In conclusion, our data suggest that the IR and IGFR activate a common
pool of PI 3-kinase that is coupled to activation of PKB and p70S6
kinase and to translocation of some GLUT4 glucose transporters. We
propose that the IR, but not the IGFR, activates an additional pool of
PI 3-kinase, which may be IRS-1-associated, and thereby mobilizes
additional GLUT4 transporters, resulting in greater stimulation of
glucose uptake. The biochemical basis of these putative discrete pools
of PI 3-kinase and their specificity in coupling to downstream
responses remains to be determined.
 |
ACKNOWLEDGEMENTS |
We are grateful to Jeremy Tavaré,
Jonathan Whittaker, Jossi Schlessinger, Tony Pawson, Morris White, Rob
Lewis, Dario Alessi, Gwyn Gould, and Steve Baldwin for providing
cDNA constructs and antibodies and to Regeneron Pharmaceuticals for
providing NT-3.
 |
FOOTNOTES |
*
This work was supported by Grants RD95/0001102 and
RD98/0001858 from the British Diabetic Association and the Medical
Research Council (to K. S.) and by a grant from the Wellcome Trust (to S. O.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 44-1223-336789;
Fax: 44-1223-331157; E-mail: ks14@mole.bio.cam.ac.uk.
 |
ABBREVIATIONS |
The abbreviations used are:
IGF, insulin-like
growth factor;
IR, insulin receptor;
IGFR, type I insulin-like growth
factor receptor;
TIR, TrkC-insulin receptor chimera;
TIGR, TrkC-IGF-I
receptor chimera;
PI 3-kinase, phosphoinositide 3-kinase;
PKB, protein
kinase B/Akt;
MAP, mitogen-activated protein;
MAPK, MAP kinase;
IRS, insulin receptor substrate;
NT-3, neurotrophin-3;
DMEM, Dulbecco's
modified Eagle's medium;
PAGE, polyacrylamide gel
electrophoresis.
 |
REFERENCES |
| 1.
|
Ebina, Y.,
Ellis, L.,
Jarnagin, K.,
Edery, M.,
Graf, L.,
Clauser, E.,
Ou, J.,
Masiarz, F.,
Kan, Y. W.,
and Goldfine, I. D.
(1985)
Cell
40,
747-758[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Ullrich, A.,
Bell, J. R.,
Chen, E. Y.,
Herrera, R.,
Petruzzeli, L. M.,
Dull, T. J.,
Gray, A.,
Coussens, L.,
Liao, Y.-C.,
Tsubokawa, M.,
Mason, A.,
Seeburg, P. H.,
Grunfeld, C.,
Rosen, O. M.,
and Ramachandran, J.
(1985)
Nature
313,
756-761[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Ullrich, A.,
Gray, A.,
Tam, A. W.,
Yang-Feng, T.,
Tsubokawa, M.,
Collins, C.,
Henzel, W.,
LeBon, T.,
Kathuria, S.,
Chen, E.,
Jacobs, S.,
Francke, U.,
Ramachandran, J.,
and Fujita-Yamaguchi, Y.
(1986)
EMBO J.
5,
2503-2512[Medline]
[Order article via Infotrieve]
|
| 4.
|
White, M. F.
(1997)
Diabetologia
40,
S2-S17
|
| 5.
|
White, M. F.,
and Yenush, L.
(1998)
Curr. Top. Microbiol. Immunol.
228,
179-208[Medline]
[Order article via Infotrieve]
|
| 6.
|
Alessi, D. R.,
and Cohen, P.
(1998)
Curr. Opin. Genet. Dev.
8,
55-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Denton, R. M.,
and Tavaré, J. M.
(1995)
Eur. J. Biochem.
227,
597-611[Medline]
[Order article via Infotrieve]
|
| 8.
|
Steele-Perkins, G.,
Turner, J.,
Edman, J. C.,
Hari, J.,
Pierce, S. B.,
Stove, C.,
Rutter, W. J.,
and Roth, R. A.
(1988)
J. Biol. Chem.
263,
11486-11492[Abstract/Free Full Text]
|
| 9.
|
Hofmann, C.,
Goldfine, I. D.,
and Whittaker, J.
(1989)
J. Biol. Chem.
264,
8606-8611[Abstract/Free Full Text]
|
| 10.
|
Weiland, M.,
Bahr, F.,
Höhne, M.,
Schürmann, A.,
Ziehm, D.,
and Joost, H. G.
(1991)
J. Cell. Physiol.
149,
428-435[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Bailyes, E. M.,
Navé, B. T.,
Soos, M. A.,
Orr, S. R.,
Hayward, A. C.,
and Siddle, K.
(1997)
Biochem. J.
327,
209-215
|
| 12.
|
Lammers, R.,
Gray, A.,
Schlessinger, J.,
and Ullrich, A.
(1989)
EMBO J.
8,
1369-1375[Medline]
[Order article via Infotrieve]
|
| 13.
|
Dandekar, A. A.,
Wallach, B. J.,
Barthel, A.,
and Roth, R. A.
(1998)
Endocrinology
139,
3578-3584[Abstract/Free Full Text]
|
| 14.
|
Kalloo-Hosein, H. E.,
Whitehead, J. P.,
Soos, M.,
Tavaré, J. M.,
Siddle, K.,
and O'Rahilly, S.
(1997)
J. Biol. Chem.
272,
24325-24332[Abstract/Free Full Text]
|
| 15.
|
Chaika, O. V.,
Chaika, N.,
Volle, D. J.,
Wielden, P. A.,
Pirrucello, S. J.,
and Lewis, R. E.
(1997)
J. Biol. Chem.
272,
11968-11974[Abstract/Free Full Text]
|
| 16.
|
Maegawa, H.,
McClain, D. A.,
Freidenberg, G.,
Olefsky, J. M.,
Napier, M.,
Lipari, T.,
Dull, T. J.,
Lee, J.,
and Ullrich, A.
(1988)
J. Biol. Chem.
263,
8912-8917[Abstract/Free Full Text]
|
| 17.
|
Takata, Y.,
Webster, N. J.,
and Olefsky, J. M.
(1991)
J. Biol. Chem.
266,
9135-9139[Abstract/Free Full Text]
|
| 18.
|
Faria, T. N.,
Blakesley, V. A.,
Kato, H.,
Stannard, B.,
LeRoith, D.,
and Roberts, C. T., Jr.
(1994)
J. Biol. Chem.
269,
13922-13928[Abstract/Free Full Text]
|
| 19.
|
Tartare, S.,
Mothe, I.,
Kowalski-Chauvel, A.,
Breittmayer, J. P.,
Balloti, R.,
and VanObberghen, E.
(1994)
J. Biol. Chem.
269,
11449-11455[Abstract/Free Full Text]
|
| 20.
|
Esposito, D. L.,
Blakesley, V. A.,
Koval, A. P.,
Scrimgeour, A. G.,
and Roith, D. L.
(1997)
Endocrinology
138,
2979-2988[Abstract/Free Full Text]
|
| 21.
|
Tavaré, J. M.,
and Siddle, K.
(1993)
Biochim. Biophys. Acta
1178,
21-39[Medline]
[Order article via Infotrieve]
|
| 22.
|
Yang, J.,
Clark, A. E.,
Kozka, I. J.,
Cushman, S. W.,
and Holman, G. D.
(1992)
J. Biol. Chem.
267,
10393-10399[Abstract/Free Full Text]
|
| 23.
|
Martin, L. B.,
Shewan, A.,
Millar, C. A.,
Gould, G. W.,
and James, D. E.
(1998)
J. Biol. Chem.
273,
1444-1452[Abstract/Free Full Text]
|
| 24.
|
Chan, C. P.,
and Krebs, E. G.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
4563-4567[Abstract/Free Full Text]
|
| 25.
|
White, M. F.,
Livingston, J. N.,
Backer, J. M.,
Lauris, V.,
Dull, T. J.,
Ullrich, A.,
and Kahn, C. R.
(1988)
Cell
54,
641-649[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Navé, B. T.,
Haigh, R. J.,
Hayward, A. C.,
Siddle, K.,
and Shepherd, P. R.
(1996)
Biochem. J.
318,
55-60
|
| 27.
|
Walker, K. S.,
Deak, M.,
Paterson, A.,
Hudson, K.,
Cohen, P.,
and Alessi, D. R.
(1998)
Biochem. J.
331,
299-308
|
| 28.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 29.
|
Holman, G. D.,
and Kasuga, M.
(1997)
Diabetologia
40,
991-1003[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Shepherd, P. R.,
Withers, D. J.,
and Siddle, K.
(1998)
Biochem. J.
333,
471-490
|
| 31.
|
Shepherd, P. R.,
Navé, B. T.,
and Siddle, K.
(1995)
Biochem. J.
305,
25-28
|
| 32.
|
Weng, Q.-P.,
Kozlowski, M.,
Belham, C.,
Zhang, A.,
Comb, M. J.,
and Avruch, J.
(1998)
J. Biol. Chem.
273,
16621-16629[Abstract/Free Full Text]
|
| 33.
|
Canagarajah, B. J.,
Khokhlatchev, A.,
Cobb, M. H.,
and Goldsmith, E. J.
(1997)
Cell
90,
859-869[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Foletta, V. C.
(1996)
Immunol. Cell Biol.
74,
121-133[Medline]
[Order article via Infotrieve]
|
| 35.
|
DeMeyts, P.,
Christofferson, C. T.,
Ursø, B.,
Wallach, B.,
Grønskov, K.,
Yakushiji, F.,
and Shymko, R. M.
(1995)
Metabolism
10,
2-11
|
| 36.
|
Zapf, A.,
Hsu, D.,
and Olefsky, J. M.
(1994)
Endocrinology
134,
2445-2452 |